Article Sidebar

PDF
Date Published: 19/08/2024
Abstract Views: 125
Views PDF: 67
DOI: https://doi.org/10.51298/vmj.v541i2.10807
Issue
Vol. 541 No. 2 (2024)
Section
Các bài báo
How to Cite
Pham, C., Duong , Q. H., Pham, X. H., Pham, Q. T., & Ngô, T. T. (2024). STUDY ON hTERT mRNA IN PERIPHERAL BLOOD IN PATIENTS WITH HEPATITIS B VIRUS - INFECTED HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 541(2). https://doi.org/10.51298/vmj.v541i2.10807

STUDY ON hTERT mRNA IN PERIPHERAL BLOOD IN PATIENTS WITH HEPATITIS B VIRUS - INFECTED HEPATOCELLULAR CARCINOMA

Châu Pham, Quang Huy Duong , Xuân Huy Pham, Quang Trung Pham, Tất Trung Ngô

Main Article Content

Abstract

Objective: To determine the rate of hTERT mRNA in peripheral blood leukocytes and the relationship between hTERT mRNA and tumor burden and disease stage according to Barcelona Clinic Liver Cancer (BCLC) in patients with hepatocellular carcinoma infected with hepatitis B virus (HBV). Subjects and methods: Cross-sectional descriptive study on 159 newly diagnosed patients with HBV-infected HCC at Military Hospital 103 and Military Central Hospital 108, using Nested-PCR combined with Realtime PCR to determine hTERT mRNA in peripheral blood leukocytes. Results: The detection rate of hTERT mRNA in peripheral blood leukocytes was 16.4%. hTERT mRNA in peripheral blood leukocytes was not associated with tumor characteristics with p > 0.05, but increased gradually with disease stage from 9.1% in stages O and A to 40% in stage D, p < 0.05. Conclusion: hTERT mRNA in peripheral blood leukocytes was detected in HCC and was related to disease stage in patients with HBV-infected HCC, so it has the potential to be a marker in the prognosis of HCC.

Article Details

Keywords

Hepatocellular carcinoma, hTERT mRNA, HBV infection

References

1. Sung H., Ferlay J., Siegel R.L. et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021. 71(3): 209-249.
2. Nault J.C., Ningarhari M., Rebouissou S. et al., The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol, 2019. 16(9): 544-558.
3. Chen X.Q., Bonnefoi H., Pelte M.F. et al., Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res, 2000. 6(10): 3823-6.
4. Miura N., Shiota G., Nakagawa T. et al., Sensitive detection of human telomerase reverse transcriptase mRNA in the serum of patients with hepatocellular carcinoma. Oncology, 2003. 64(4): 430-4.
5. Zhou X., Lu J., Zhu H. Correlation between the expression of hTERT gene and the clinicopathological characteristics of hepatocellular carcinoma. Oncol Lett, 2016. 11(1): 111-115.
6. Reig M., Forner A., Rimola J. et al., BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol, 2022. 76(3): 681-693.
7. Nguyen H.B., Le X.T., Nguyen H.H. et al. Diagnostic Value of hTERT mRNA and in Combination With AFP, AFP-L3%, Des-γ-carboxyprothrombin for Screening of Hepatocellular Carcinoma in Liver Cirrhosis Patients HBV or HCV-Related. Cancer Inform 2022, 21: 1-8.
8. Goldvaser H., Gutkin A., Beery E. et al., Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: a potential pan-cancer marker. Br J Cancer, 2017. 117(3): 353-357.
9. Gertler R., Rosenberg R., Fuehrer K. et al., Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res, 2003. 162: 149-55.
10. Schulze K., Gasch C., Staufer K. et al., Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer, 2013. 133(9): 2165-71.